RXRX

Recursion Pharmaceuticals, Inc.

8.35 USD
-0.01 (-0.12%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Recursion Pharmaceuticals, Inc. stock is down -11.55% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 July’s closed higher than June. In the last 10 Unusual Options Trades, there were 6 PUTs, 4 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
10 Jul 15:19 16 Jan, 2026 5.00 PUT 299 1004
10 Jul 15:20 16 Jan, 2026 5.00 PUT 211 1004
11 Jul 13:32 20 Sep, 2024 8.00 CALL 1000 1445
11 Jul 14:15 16 Jan, 2026 5.00 CALL 100 655
11 Jul 14:43 20 Dec, 2024 10.00 PUT 300 428
11 Jul 17:32 17 Jan, 2025 7.50 PUT 650 3397
11 Jul 19:14 17 Jan, 2025 10.00 PUT 73 1224
12 Jul 15:07 16 Aug, 2024 7.00 CALL 200 552
12 Jul 16:31 16 Jan, 2026 10.00 CALL 100 1576
12 Jul 17:52 20 Dec, 2024 7.00 PUT 288 295

About Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation. REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer.